HITACHI-CONSTRUCTION
Hitachi Construction Machinery Co., Ltd. (TOKYO: 6305) (“HCM”) is pleased to announce its vision for autonomous mining — an open, interoperable ecosystem of partners that integrate their systems alongside existing mine infrastructure.
Grounded in support for ISO Standards and a drive to encourage new entrants into the mining industry, HCM is pioneering this open and interoperable approach to autonomy among global mining technology leaders. With this announcement, HCM is publicly declaring support for standards-based autonomy and is offering its interoperable technology to assist mining customers in integrating new vendors into their existing infrastructure. HCM’s support for open, interoperable autonomy is based on its philosophy for its partner-focused Solution Linkage platform.
“Open innovation is the guiding technological philosophy for Solution Linkage,” says Vice President and Executive Officer, Chief Technology Officer Hideshi Fukumoto. “Based on this philosophy, HCM is announcing its commitment to championing the customer enablement of autonomous mining through an open, interoperable ecosystem of partner solutions.
“We believe this open approach provides customers the greatest flexibility and control for integrating new autonomous solutions into their existing operations while reducing associated risks and costs of alternative approaches.”
The HCM Group is developing this open autonomy approach under the
Solution Linkage initiative, a platform already available to HCM's
customers in the construction industry now being made available to
mining customers with support from HCM subsidiary Wenco International
Mining Systems (Wenco). Solution Linkage is a standards-based platform
grounded on three principles:
Open Innovation, Interoperability,
and Partner Ecosystem.
In this context, Open Innovation means the HCM Group’s support for open standards to enable the creation of multi-vendor solutions that reduce costs and increase value for customers. By designing solutions in compliance with ANSI/ISA-95 and ISO standards for autonomous interoperability, Solution Linkage avoids vendor lock-in and offers customers the freedom to choose technologies from preferred vendors independent of their fleet management system. This approach future-proofs customer technology infrastructure, providing a phased approach for their incorporation of new technologies as they emerge. This approach also benefits autonomy vendors who are new to mining, since they will be able to leverage a HCM's technology and experience in meeting the requirements of mining customers.
The HCM Group’s key capability of Interoperability creates simplified connectivity between systems to reduce operational silos, enabling end-to-end visibility and control across the mining value chain. Customers using Solution Linkage can connect autonomous equipment from multiple vendors into existing fleet management and operations infrastructure. Interoperability also affords mines a systems-level understanding of their pit-to-port operation, providing access to more robust data analytics and process management. This capability enables mine management to make superior decisions based on operation-wide insight that deliver end-to-end optimization.
HCM's open autonomy approach rests on creating a Partner Ecosystem in which customers and third-party partners can leverage HCM’s experience and open platform to successfully provide autonomous functionality and reduce the risk of technological adoption. This initiative is already working with a global mining leader to integrate non-mining OEM autonomous vehicles into their existing mining infrastructure. Likewise, HCM is actively seeking customer and vendor partnerships to further extend the value of this open, interoperable platform. If autonomy vendors have already been selected by a customer and are struggling to integrate into the client’s existing fleet management system or mine operations, Hitachi may be able to help using the Solution Linkage platform.
The HCM Group will reveal further details of its approach to open autonomy and Solution Linkage in a presentation at the CIM 2019 Convention, running April 28 to May 1 at the Palais de Congrès in Montreal, Canada. Fukumoto and other senior executives from Hitachi and Wenco will discuss this strategy and details of Hitachi’s plans for mining in several presentations throughout the event. The schedule of Hitachi-related events is as follows:
- Sunday, April 28, 4:30 PM — A welcome speech at the event’s Opening Ceremonies by Wenco Board Member and HCM Executive Officer David Harvey;
- Monday, April 29, 10:00 AM — An Innovation Stage presentation on the Solution Linkage vision for open autonomy by Wenco Board Member and HCM Vice President and Executive Officer, CTO Hideshi Fukumoto;
- Monday, April 29, 12:00 PM — Case Study: Accelerating Business Decisions and Mine Performance Through Operational Data Analysis at an Australian Coal Operation technical breakout presentation by Wenco Executive Vice-President of Corporate Strategy Eric Winsborrow;
- Monday, April 29, 2:00 PM — Toward an Open Standard in Autonomous Control System Interfaces: Current Issues and Best Practices technical breakout presentation by Wenco Director of Technology Martin Politick;
- Tuesday, April 30, 10:00 AM — An Innovation Stage presentation on Hitachi’s vision for data and IoT in mining by Wenco Executive Vice-President of Corporate Strategy Eric Winsborrow;
- Wednesday, May 1, 4:00 PM — A concluding speech at the event’s closing luncheon by Wenco Board Member and HCM General Manager of Solution Business Center Yoshinori Furuno.
These presentations further detail the ongoing work of HCM and support the core message about open, interoperable, partner ecosystems.
To learn more about the HCM announcement in support of open and interoperable mining autonomy, Solution Linkage, or other HCM's solutions, please contact the HCM Group company representatives.
About Hitachi Construction Machinery
Hitachi, Construction Machinery Co., Ltd., (TOKYO: 6305), headquartered in Tokyo, Japan, is a global Construction Machinery company with approximately 24,000 employees worldwide. Fiscal 2017 (ended March 31, 2018) consolidated revenues totaled 959 billion yen. Hitachi Construction Machinery will focus more than ever on the Construction and Mining Machinery Business, which includes Hydraulic Excavators, Wheel Loaders, Rigid Dump Trucks, Compaction Equipment, Applications and Mine Management Systems. For more information on Hitachi Construction Machinery, please visit the company's website at https://www.hitachicm.com/global/
About Wenco International Mining Systems
For over 30 years, Wenco has developed technology solutions to help mining companies increase productivity. Wenco offers a suite of mine productivity solutions including Fleet Management, Asset Health, Proximity Detection, Mining Business Analytics & High Precision Machine Guidance Solutions. Wenco works closely with customers to enable them to extract unrealized value from their operations and strives to be recognized as the industry leader for reliable solutions in mine safety, productivity, and efficiency. A Hitachi company since 2009, Wenco is a wholly owned subsidiary of Hitachi Construction Machinery, with headquarters in Vancouver, Canada. For more information, please visit www.wencomine.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190425005494/en/
Contact:
Hitachi Construction Machinery
Business AHS Marketing, Global Mining | hitachiahs@hcm-mining.com Public Relations Masayoshi Yamaji, Public Relations & Investor Relations Dept. | public_relations@hitachi-kenki.comWenco International Mining Systems
Geoff Gauthier | ggauthier@wencomine.comLink:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom